Pure Global AI
NCT06411678Not yet recruiting

Application of 68GA-labeled CD73 Targeting Probe PET/CT Imaging in the Diagnosis of Breast Cancer

Peking Union Medical College HospitalPhase 1ClinicalTrials.govdrug
Verified
Study focus
Disease/Condition
Breast Cancer
Drug/Device/Intervention
68GA-DOTA-dPNE
Study type
Interventional
Intervention type
drug
Sponsor & location
Primary sponsor
Peking Union Medical College Hospital
Location
Dongcheng, China
Timeline & enrollment
Phase
Phase 1
Start date
May 10, 2024
End date
Jun 01, 2026
Enrollment
50 participants
Primary outcome

The evaluation of diagnostic performance of 68Ga-DOTA-dPNE PET in breast cancer

Summary

We plan to conduct a 68Ga-DOTA-dPNE PET/CT imaging study on breast cancer patients to observe
 the binding of the tracer to lesions and evaluate CD73 expression. Alongside this, we will
 correlate these imaging results with relevant clinical indicators to assess the effectiveness
 of 68Ga-DOTA-dPNE in diagnosing and guiding treatment in breast cancer patients. This study
 aims to predict responses to targeted therapies.

ICD-10 classifications
Malignant neoplasm of breastMalignant neoplasm of breastCarcinoma in situ of breast, unspecifiedMalignant neoplasm: Breast, unspecifiedOther carcinoma in situ of breast
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06411678
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT06411678 through Pure Global AI's free database. This Phase 1 trial is sponsored by Peking Union Medical College Hospital and is currently Not yet recruiting. The study focuses on Breast Cancer. Target enrollment is 50 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.